Claims:

1. Use of an isolated anti-Factor XI (FXI) antibody or antigen-binding fragment thereof in the manufacture of a medicament for the treatment of a thromboembolic disorder in a subject in need thereof, wherein the antibody or antigen-binding fragment comprises a heavy chain variable region (VH) comprising complementary determining regions HCDR1, HCDR2, and HCDR3 in SEQ ID NO: 9 or 29; and a light chain variable region (VL) comprising complementary determining regions LCDR1, LCDR2, LCDR3 in SEQ ID NO: 19 or 39.

2. The use of claim 1, wherein the antibody or antigen-binding fragment thereof comprises:

i. a heavy chain variable region CDR1 of SEQ ID NO: 23; a heavy chain variable region CDR2 of SEQ ID NO: 24; a heavy chain variable region CDR3 of SEQ ID NO: 25; a light chain variable region CDR1 of SEQ ID NO: 33; a light chain variable region CDR2 of SEQ ID NO: 34; and a light chain variable region CDR3 of SEQ ID NO: 35;

ii. a heavy chain variable region CDR1 of SEQ ID NO: 26; a heavy chain variable region CDR2 of SEQ ID NO: 27; a heavy chain variable region CDR3 of SEQ ID NO: 28; a light chain variable region CDR1 of SEQ ID NO: 36; a light chain variable region CDR2 of SEQ ID NO: 37; and a light chain variable region CDR3 of SEQ ID NO: 38;

iii. a heavy chain variable region CDR1 of SEQ ID NO: 43; a heavy chain variable region CDR2 of SEQ ID NO: 44; a heavy chain variable region CDR3 of SEQ ID NO: 45; a light chain variable region CDR1 of SEQ ID NO: 47; a light chain variable region CDR2 of SEQ ID NO: 37; and a light chain variable region CDR3 of SEQ ID NO: 15; or

iv. a heavy chain variable region CDR1 of SEQ ID NO: 46; a heavy chain variable region CDR2 of SEQ ID NO: 4; a heavy chain variable region CDR3 of SEQ ID NO: 5; a light chain variable region CDR1 of SEQ ID NO: 33; a light chain variable region CDR2 of SEQ ID NO: 14; and a light chain variable region CDR3 of SEQ ID NO: 15.

3. The use of claim 1, wherein the antibody or antigen-binding fragment comprises a heavy chain variable region (VH) selected from the group consisting of SEQ ID NO: 9 and 29; and a light chain variable region (VL) selected from the group consisting of SEQ ID NO: 19 and 39.

4. The use of claim 1, wherein the antibody or antigen-binding fragment comprises a variable heavy chain sequence comprising the amino acid sequence of SEQ

ID NO: 9; and variable light chain sequence comprising the amino acid sequence of SEQ ID NO: 19.

5. The use of claim 1, wherein the antibody or antigen-binding fragment comprises a variable heavy chain sequence comprising the amino acid sequence of SEQ ID NO: 29 and a variable light chain sequence comprising the amino acid sequence of SEQ ID NO: 39.

6. The use of claim 1, wherein the antibody comprises a heavy chain comprising an amino acid of SEQ ID NO: 31 and a light chain comprising an amino acid of SEQ ID NO: 41.

7. The use of claim 1, wherein the antibody comprises a heavy chain comprising the amino acid sequence of SEQ ID NO: 11 and a light chain comprising the amino acid sequence of SEQ ID NO: 21.

8. The use of claim 1, wherein the antibody is a human monoclonal antibody.

9. The use of claim 1, wherein the antibody is a human or humanized IgG1 isotype.

10. The use of any one of claims 1-9, wherein the subject is afflicted with one or more of ischemic stroke associated with atrial fibrillation and deep vein thrombosis.

11. The use of claim 10, wherein the subject is afflicted with ischemic stroke associated with atrial fibrillation.

12. The use of any one of claims 1-9, wherein the treatment further comprises administering to the subject one or more statin therapies.

13. The use of claim 12, wherein the antibody or antigen-binding fragment and the one or more statin therapies are manufactured in the same medicament.